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Regulator of G-protein signaling (RGS) proteins are
GTPase activating proteins (GAPs) of heterotrimeric G-
proteins that alter the amplitude and kinetics of recep-
tor-promoted signaling. In this study we defined the
G-protein -subunit selectivity of purified Sf9 cell-de-
rived R7 proteins, a subfamily of RGS proteins (RGS6, -7,
-9, and -11) containing a G-like (GGL) domain that me-
diates dimeric interaction with G5. G5/R7 dimers stim-
ulated steady state GTPase activity of G-subunits of
the Gi family, but not of Gq or G11, when added to
proteoliposomes containing M2 or M1 muscarinic recep-
tor-coupled G-protein heterotrimers. Concentration ef-
fect curves of the G5/R7 proteins revealed differences
in potencies and efficacies toward G-subunits of the Gi
family. Although all four G5/R7 proteins exhibited sim-
ilar potencies toward Go, G5/RGS9 and G5/RGS11
were more potent GAPs of Gi1, Gi2, and Gi3 than were
G5/RGS6 and G5/RGS7. The maximal GAP activity ex-
hibited by G5/RGS11 was 2- to 4-fold higher than that of
G5/RGS7 and G5/RGS9, with G5/RGS6 exhibiting an
intermediate maximal GAP activity. Moreover, the less
efficacious G5/RGS7 and G5/RGS9 inhibited G5/
RGS11-stimulated GTPase activity of Go. Therefore, R7
family RGS proteins are Gi family-selective GAPs with
potentially important differences in activities.
Heterotrimeric guanine nucleotide-binding proteins (G-pro-
teins) act as molecular switches in multiple GPCR1 signaling
pathways via regulation of specific effector molecules such as
phospholipase C and adenylyl cyclase. The biological activity of
G-protein -subunits is determined by the identity of the bound
guanine nucleotide (GTP or GDP), which in turn is governed by
the relative rates of guanine nucleotide exchange and hydrol-
ysis of GTP by the intrinsic GTPase activity of G-subunits.
These opposing reactions are stimulated by agonist-occupied
GPCR and GTPase-activating proteins (GAPs).
Although some effector proteins exhibit GAP activity (1–3),
the primary regulators of GTPase activity of G-subunits are a
diverse family of regulator of G-protein signaling (RGS) pro-
teins that act as GAPs for heterotrimeric G-protein -subunits
(4–7). This family is defined by a conserved RGS domain,
which markedly increases the rate of GTP hydrolysis by G-
subunits and terminates effector activation by both G- and
G-subunits. More than 30 RGS proteins have been identified
and organized into subfamilies based on sequence similarity
and domain structure. These families vary in size and complex-
ity, from the R4 family whose structure is largely limited to the
RGS domain to the R12 and RhoGEF families whose members
are large multifunctional proteins containing several domains
(for reviews see Refs. 8–10).
The R7 RGS family is a unique multidomain family, which
consists of RGS proteins containing a novel G--like (GGL)
domain homologous to the G-subunit of heterotrimeric G-
proteins (11). This domain, found in the mammalian proteins
RGS6, -7, -9, and -11 and the Caenorhabditis elegans proteins
EAT16 and EGL10 (7, 12), confers specific binding to G5-
subunits but not to G1–4 (11, 13). Heterodimeric association
with G5 appears necessary for stability and biological activity
of R7 proteins (14–16). R7 proteins also contain a conserved
N-terminal DEP (dishevelled, EGL10, pleckstrin homology) do-
main of unknown function (17).
RGS proteins may modify GPCR signaling through selective
increases in GTP hydrolysis by a subset of G-proteins. For
example, RZ family members specifically accelerate GTPase
activity of Gz (18), and the recently characterized sorting
nexin 13 (RGS-PX1) has been reported to increase the rate of
GTP hydrolysis by Gs but not by Gi (19). The G-protein
selectivity of the R7 family of RGS proteins has not been clearly
defined. In single turnover GTPase assays, G5/RGS6 and G5/
RGS7 increased GTPase activity of Go (20) and G5/RGS11
increased GTPase activity of Go and, to a much lesser degree,
that of Gi1, Gi2, and Gi3 (11). However, the R7 RGS proteins
did not affect the single turnover GTPase rates of other G-
subunits, including Gq (R183C), Gs, and G12. In contrast,
when expressed in cultured cell lines, RGS7 inhibited Gq-
promoted Ca2 responses downstream of M3 receptors (14)
and 5-HT2c receptors (21, 22) and inhibited Gi-regulated K

channel activity in a G5-dependent manner (23). Therefore,
assays of soluble G-subunits suggest Go selectivity, while
intact cell signaling studies implicate R7 proteins in regulation
of Gq as well as Gi pathways.
In face of the uncertainty of the actions of R7 RGS proteins,
we purified the four members of the mammalian R7 family.
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The specificities of action of G5/R7 heterodimers were deter-
mined in steady state GTPase assays of Gi and Gq family
G-subunits reconstituted with GPCR in phospholipid vesicles.
G5/RGS6, -7, -9, and -11 increased the GTPase activity of Go,
Gi1, Gi2, and Gi3 but not Gq or G11. Notable differences
in maximal GAP activities were observed among R7 family
proteins, and the maximal activity of the most efficacious
RGS protein (G5/RGS11) was inhibited by G5/RGS7 and
G5/RGS9.
EXPERIMENTAL PROCEDURES
Protein Purification—The generation of baculoviruses for G5,
RGS6, RGS7, and RGS11 have been described previously (11, 20). A
baculovirus for RGS9–1 in pFastbac Htb was prepared similarly. Cul-
tures of Sf9 insect cells (1.4  106 cells/ml) were co-infected with virus
encoding the RGS6, RGS7, or RGS9 gene (m.o.i. of 1) and a hexahisti-
dine-tagged G5 (short isoform) (m.o.i. of 0.5). Forty-eight hours postin-
fection, 4 liters of cells were collected by centrifugation. Due to lower
expression under these conditions, Sf9 cells were infected with the
RGS11:G5 viruses at a 10:1 ratio (m.o.i. of 0.5 and 0.05), and cell
lysates were obtained 65 h postinfection. Cells were resuspended and
lysed in 600 ml of Buffer A (20 mM KPO4, pH 8, 150 mM NaCl, 2 mM
MgCl2, 5 mM -mercaptoethanol, protease inhibitors (500 nM aprotinin,
10 M leupeptin, 200 M phenylmethylsulfonyl fluoride, 1 nM pepstatin,
10 M L-1-chloro-3-(4-tosylamido)-4-phenyl-2-butanone)) with 20
strokes of a Dounce homogenizer at 4 °C. The lysate was cleared by low
speed centrifugation, and the supernatant was centrifuged at
100,000  g for 30 min. The soluble protein fraction was loaded on a 3-
to 5-ml column of Ni-NTA-agarose resin (Qiagen, Germany) over 3 h.
The column was washed with 15 ml of Buffer B (20 mM KPO4, pH 8, 400
mM NaCl, 2 mM MgCl2, 5 mM -mercaptoethanol, and protease inhibi-
tors) followed by 5 ml of Buffer C (20 mM KPO4, pH 8, 25 mM NaCl, 2 mM
MgCl2, 5 mM -mercaptoethanol, and protease inhibitors). The G5/R7
dimers eluted with 50–150 mM imidazole in Buffer C. This eluate was
further purified using 1 ml of HighTrap FPLC columns of either Q-
Sepharose (G5/RGS6 and G5/RGS7) or S-Sepharose (G5/RGS9 and
G5/RGS11) (Amersham Biosciences). The Ni-NTA eluate was diluted
5:1 in starting buffer for ion exchange chromatography (buffer for
Q-Sepharose: 50 mM Tris, pH 8, 2 mM dithiothreitol, protease inhibitors;
buffer for S-Sepharose: 50 mM Hepes, pH 8, 1 mM EDTA, 2 mM dithio-
threitol, 10% glycerol, protease inhibitors), loaded onto the FPLC col-
umn, and eluted in the same buffer with a 0–400 mM NaCl gradient
over 30-column volumes. Each dimer eluted at 200 mM NaCl. Frac-
tions were collected and concentrated using a Centricon centrifugal
filter device (Millipore, Bedford, CT). The concentration of purified
G5/R7 dimers was determined by Coomassie staining purified product
and a standard curve of protein standards resolved by SDS-PAGE.
Yield was 1 mg of G5/R7 dimer per 4 liters except for G5/RGS11,
whose purification yielded 250 g per 4 liters. G- and G-subunits
(24) and muscarinic receptors (25) were purified after expression from
baculoviruses in Sf9 insect cells as described.
Vesicle Reconstitution and Characterization—Detergent/phospho-
lipid mixed micelles were prepared by drying 110 g of phosphati-
dylethanolamine, 70 g of phosphatidylserine, and 8 nmol of cholesteryl
hemisuccinate under argon and resuspending in detergent buffer (0.4%
deoxycholate, 20 mM Hepes, 1 mM EDTA, 100 mM NaCl). Fifty l of this
preparation was combined with 15 pmol of muscarinic receptor, 50 pmol
of G, and 150 pmol of G12 in Buffer D (20 mM Hepes, 100 mM NaCl,
1 mM EDTA, 2 mM MgCl2) and immediately loaded onto a G-50-Sepha-
rose column equilibrated with Buffer D. The eluate was collected in
200-l fractions. Fractions were assayed for the presence of muscarinic
receptor by incubation of 5 l per fraction with 20 nM [3H]quinuclidinyl
benzilate (200,000 cpm) in a volume of 100 l for 90 min at 30 °C and
filtration over GF/F filters (Whatman). Peak fractions also were as-
sayed for G incorporation by incubation of 5 l of the vesicle prepara-
tion with 1 M 35S-labeled GTPS (500,000 cpm) in the presence or
absence of 0.1% C12E10 detergent (total volume  100 l) at 30 °C for 90
min. Samples labeled in the absence of C12E10 were filtered over GF/F
filters, which collect vesicles but not free protein, to quantitate incor-
poration of G-subunits into vesicles, and C12E10-containing samples
were filtered over nitrocellulose to quantitate total G.
Steady State GTPase Assays—One microliter (for Gi/o-containing
vesicles) or 5 l (for Gq/11-containing vesicles) of the vesicle prepara-
tions was equilibrated on ice in Buffer D in the presence or absence of
100 M carbachol and various concentrations of RGS protein.
[-32P]GTP (2 M; 400,000 cpm) was added to each 25 l of reaction.
The reaction was transferred to a 30 °C water bath for 15 min (for
Gi/o-containing vesicles) or 30 min (for Gq/11-containing vesicles) and
quenched on ice with 975 ml of cold 5% activated charcoal in 20 mM
NaH2PO4. The charcoal was pelleted by centrifugation, and a portion of
the supernatant was added to scintillant for 32Pi quantitation.
RESULTS
The specificity of RGS proteins for G-protein substrates de-
termines in part their physiological effects on signaling. Previ-
ous in vitro studies with G-subunits in solution have illus-
trated specificity of R7-RGS proteins for Go, whereas in vivo
observations have suggested broader activities. To more specif-
ically address the selectivity of individual G5/R7 heterodimers
for G-subunits, we purified G5/RGS6, G5/RGS7, G5/RGS9,
and G5/RGS11 to near homogeneity and directly measured
their selectivity in steady state GTPase assays with proteoli-
posomes reconstituted with M1 or M2 muscarinic receptors and
various heterotrimeric G proteins of the Gq and Gi families,
respectively.
G5/R7 Protein Purification—Full-length RGS6, -7, -9, and
-11 were co-expressed with hexahistidine-tagged G5 in Sf9
insect cells using the baculovirus expression system. Dimers
were purified from the soluble fraction using Ni-NTA-agarose
and ion exchange chromatography. Twenty-five to seventy-five
percent of the total cellular immunoreactive R7 protein was
recovered in the soluble fraction, 25–75% of the soluble protein
was recovered following Ni-NTA chromatography, and nearly
100% of the Ni-NTA eluate was recovered following the final
ion exchange purification. The results of a typical purification
(G5/RGS7) are shown in Fig. 1A. Purified G5/RGS6, G5/
RGS9, and G5/RGS11 dimers are illustrated in Fig. 1B.
Vesicle Reconstitution—G-protein -subunits (Go, Gi1,
Gi2, Gi3, Gq, G11) were reconstituted in phospholipid ves-
icles with G12 and either M1 (Gq family G-proteins) or M2 (Gi
family G-proteins) muscarinic receptors under conditions sim-
FIG. 1. G5/R7 purification. A, the purification of G5/RGS7 is
shown on a Coomassie Blue-stained SDS-PAGE. The soluble fraction of
Sf9 cells infected with RGS7 and hexahistidine-tagged G5 was loaded
onto a Ni-NTA column. The column was consecutively washed with 400
mM NaCl (lane 1), 25 mM NaCl (lane 2), 50 mM imidazole (lane 3), 150
mM imidazole (lane 4), and 300 mM imidazole (lane 5). The 50 mM
imidazole elution was further purified on a HighTrap Q anionic ex-
change column and eluted with a gradient of 0–400 mM NaCl. Lanes
6–13 show fractions eluting at 175–225 mM NaCl. Fractions shown in
lanes 9–11 were pooled and concentrated. B, the final purified products
of all four G5/R7 dimers are shown: G5/RGS6 (lane 1), G5/RGS7
(lane 2), G5/RGS9 (lane 3), and G5/RGS11 (lane 4).
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ilar to those described by Ross and coworkers (26, 27). Recovery
of G-subunits and M1 or M2 muscarinic receptors in the
various vesicle preparations was quantitated as described un-
der “Experimental Procedures.” Essentially 100% of added
Go, Gi1, Gi2, or Gi3 was incorporated into vesicles, and
receptor recovery in the proteoliposomes was 50%. We also
prepared and resolved Go-containing vesicles using the higher
exclusion limit Sephacryl S-300 gel filtration resin, which sep-
arates vesicles from free Go, and observed nearly all of the Go
immunoreactivity co-migrating with vesicles in the void vol-
ume (data not shown). The four varieties of M2Gi/o vesicles
contained similar G protein levels (100 fmol/l) and recep-
tor: G ratios (1:6) (data not shown). Quantitation of Gq and
G11 is difficult due to the low rates of guanine nucleotide
turnover by these G-subunits. Therefore, calculations of
GTPase activity reported below were made assuming that in-
corporation of Gq/11 into vesicles was equal to that of Gi family
G-subunits.
Steady State GTPase Assays—The GAP activity of G5/R7
proteins toward G-subunits of the Gi and Gq families was
assessed in steady state GTPase assays, which measure mul-
tiple rounds of GTP hydrolysis and, as such, reflect both gua-
nine nucleotide exchange and GTPase activity. RGS4, an effec-
tive GAP against Gq and Gi family G-subunits (28), was used
as a reference RGS protein in all experiments. Only minor
increases were observed in the rate of GTP hydrolysis in the
presence of either agonist (100 M carbachol) or GAP (200 nM
RGS4) alone in proteoliposomes formed by reconstitution of M2
muscarinic receptor, Go, and G12 (Fig. 2). In contrast, the
combined presence of carbachol and RGS4 resulted in a mark-
edly synergistic increase in GTPase activity, and the rate of
hydrolysis of GTP was linear for at least 15 min.
In the presence of a maximally effective concentration of
RGS protein, guanine nucleotide exchange is rate-limiting, and
therefore stimulation of GTPase activity by carbachol was ob-
served with a concentration dependence of agonist that approx-
imated its occupancy curve for binding to the M2 muscarinic
receptor (data not shown). Similarly, in the presence of a max-
imally effective concentration of carbachol, guanine nucleotide
exchange was no longer rate-limiting, and marked concentra-
tion-dependent stimulation of GTPase was observed with
RGS4 (data not shown) and G5/R7 RGS proteins (see below).
G5/R7 Proteins Stimulate Steady State GTPase Activity of
Gi Family G-subunits—To compare the capacity of G5/R7
proteins to accelerate GTPase rates of Gi family G-subunits,
steady state GTPase activities were determined in the presence
and absence of 100 M carbachol and in the presence and
absence of 1 M RGS protein (either RGS4 or each G5/R7
dimer). RGS4 markedly increased GTPase activity for Go,
Gi1, Gi2, and Gi3 in the presence of 100 M carbachol (Fig.
3). Each of the G5/R7 dimers also stimulated to varying de-
grees GTP hydrolysis by Go, Gi1, Gi2, and Gi3 in the
presence of agonist (Fig. 3 and Table I). The rate observed with
G5/RGS11 was as high or higher than the rate with RGS4
with all four Gi family G-subunits, while the GTPase rates in
the presence of 1 M G5/RGS6, G5/RGS7, and G5/RGS9
were significantly lower. Vesicles containing Go achieved the
highest maximal GTPase rates irrespective of the RGS protein.
However, the basal rate of GTP hydrolysis by Go in the ab-
sence of RGS protein was also higher than that observed in
GI-containing vesicles. Thus, the fold increase in activity
(GTPase rate in the presence of RGS and agonist divided by the
GTPase rate with agonist alone) of Gi3 was as high or higher
than that of Go in response to G5/RGS6, -7, -9, and -11
stimulation. Further, the effects of R7 proteins on GTPase
activity of Go-subunits reconstituted with purified P2Y12 re-
ceptors was also determined (in the presence of the agonist
2-methylthio ADP). Similar to the results observed with M2
receptor-coupled G-proteins, each of the G5/RGS11 dimers
stimulated steady state GTPase activity of Go, and G5/
RGS11 stimulated much higher GTPase rates than the other
R7 proteins (data not shown).
G5/R7 Proteins Do Not Stimulate Steady State GTPase Activ-
ity of Gq Family G-subunits—Regulation of GTPase activities of
Gq and G11 was examined in vesicles reconstituted with M1
muscarinic receptor and heterotrimeric G-proteins (Fig. 4). RGS4
increased steady state GTPase activity of Gq and G11 in the
presence of agonist by nearly 5-fold to final GTPase rates of 200
fmol of GTP/min/pmol of G. Consistent with previous observa-
tions of guanine nucleotide exchange/GTPase kinetics of Gq (29),
these rates are lower than those observed for Gi family -sub-
units. In contrast to the activity of RGS4, none of the G5/R7
dimers significantly increased steady state GTPase activity of
Gq or G11 in the presence of carbachol (Fig. 4A). Likewise,
G5/R7 dimers did not stimulate GTPase activity of Gq- or
G11-subunits reconstituted with purified P2Y1 receptors (in the
presence of the agonist 2-methylthio ADP) (data not shown).
Further, 1 M G5/R7 dimers had no effect on the GTPase activ-
ity of M1 receptor-coupled Gq and G11 stimulated by RGS4 and
carbachol (Fig. 4B). The partial inhibition observed with G5/
RGS11 was nonspecific as demonstrated by equivalent inhibitory
activity observed with boiled G5/RGS11. Therefore, under the
conditions of these assays, R7 proteins neither stimulate GTPase
activity of Gq or G11 nor affect GTPase activity stimulated by
agonist and RGS4.
G5/R7 Proteins Exhibit Differences in Maximal Activity and
Potency toward Gi Family G-subunits—To more fully elucidate
any selectivity of G5/R7 proteins as GAPs for Gi family subunits,
full concentration effect curves of each G5/R7 protein were gen-
erated in the presence of a maximally effective concentration of
carbachol. Consistent with the data in Fig. 3, maximally effective
concentrations of G5/RGS11 produced larger effects than G5/
RGS7, G5/RGS6, and G5/RGS9 on the GTPase activity of each
G-subunit (Fig. 5 and data not shown), and the highest maximal
rate observed with each RGS protein was observed with Go as
substrate (not shown). Each of the G5/RGS dimers produced a
near maximal effect at a concentration of 1 M, and therefore
each activation curve was normalized to 100% of maximal activ-
ity for comparison of EC50 values (Fig. 6). All four G5/R7 dimers
FIG. 2. Steady state GTPase activity of reconstituted G-sub-
units. The time course of GTP hydrolysis by Go reconstituted in
phospholipid vesicles with the M2 muscarinic receptor and G12 under
basal conditions (E), in the presence of 100 M carbachol (Œ), 200 nM
RGS4 (), or carbachol plus RGS4 () is shown.
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exhibited similar potency for Go (EC50  16–47 nM), while
G5/RGS9 and G5/RGS11 were more potent (EC50  25–80 nM)
than G5/RGS6 and G5/RGS7 (EC50  150–350 nM) for Gi1,
Gi2, and Gi3 (Table II).
G5/RGS7 and G5/RGS9 Inhibit G5/RGS11-stimulated
Go GTPase Activity—Marked differences in the maximal
GTPase rate of G-subunits were observed across the G5/R7
protein family. For example, G5/RGS11-stimulated GTPase
activity of Go was twice that achieved in the presence of
G5/RGS9 or G5/RGS7. These results suggest that G5/RGS7
and G5/RGS9 interaction with G-proteins results in a less
active G conformation with respect to GTPase activity than
that promoted by G5/RGS11 interaction. To test this hypoth-
esis, steady state GTPase activity of M2Go12 vesicles was
measured in the presence of 100 nM G5/RGS11 or 1 M G5/
RGS7 alone or with 100 nM G5/RGS11 plus 1 M G5/RGS7.
As illustrated in Fig. 7A, GTPase activity in the presence of
G5/RGS11 was nearly twice that observed with a 10-fold
higher concentration of G5/RGS7. However, the combined
presence of 1 M G5/RGS7 and 100 nM G5/RGS11 resulted in
activity only slightly greater than that of G5/RGS7 alone,
suggesting that G5/RGS7 competitively antagonizes the ac-
tion of the more efficacious G5/RGS11. Heat-inactivated G5/
RGS7 neither stimulated GTPase activity nor inhibited the
stimulatory effect of G5/RGS11 on GTPase activity (Fig. 7A),
demonstrating that both effects of G5/RGS7 are dependent on
protein activity. To further characterize the interaction of RGS
proteins and Go, the concentration dependence of the inhibi-
tory effect of G5/RGS7 and G5/RGS9 was determined by
varying the concentrations of these proteins in the presence of
carbachol and 100 nM G5/RGS11. Both G5/RGS7 and G5/
RGS9 significantly inhibited G5/RGS11-stimulated GTPase
activity of M2Go vesicles with IC50 values of 100–200 nM (Fig.
7B). These data indicate that while G5/RGS7 and G5/RGS9
are less efficacious activators of GTPase activity, they interact
with a similar region of Go as does G5/RGS11.
DISCUSSION
The results of this study demonstrate Gi/o specificity of
G5/R7 proteins and found no evidence of regulation of Gq
GTPase activity by these proteins. Further, we demonstrated
that differences exist in the potencies and relative efficacies of
the G5/R7 proteins for their Gi/o substrates. Finally, we il-
lustrated that G5/RGS7 and G5/RGS9, which are less effec-
tive promoters of maximal GTPase activity than is G5/RGS11,
inhibit G5/RGS11-stimulated GTPase activity of Go.
The drug selectivity of G-protein-coupled receptors has been
widely exploited therapeutically to manipulate specific cellular
processes (30–34). Similarly, selectivities of G-proteins for effec-
tor activation and potential selectivities of RGS proteins for de-
activation of G-proteins may provide equally rich targets for
pharmacological modulation of G-protein-regulated signaling
(35, 36). Whereas the role of receptor activity and selectivity in
regulating various classes of G-proteins has been studied exten-
sively in the past decades, the roles of proteins exhibiting G
FIG. 3. G5/R7 proteins stimulate
GTPase activity of Gi family G-sub-
units. The effects of 100 M carbachol
and 1 M of the indicated RGS protein on
the steady state GTPase activity of Go,
Gi1, Gi2, and Gi3 reconstituted in
phospholipid vesicles with the M2 musca-
rinic receptor and G12 were determined
as described under “Experimental Proce-
dures.” Open bars, no agonist. Shaded
bars, 100 M carbachol. Results shown
are representative of at least three sepa-
rate experiments using three independ-
ent vesicle preparations.
TABLE I
GTPase rates of Gi family G-subunits in the presence of RGS4 and G5/R7 proteins
GTPase rates (min1) attained in the presence of 100 M carbachol and 1 M RGS protein are shown with mean  S.D.
G5/RGS6 G5/RGS7 G5/RGS9 G5/RGS11 RGS4
Go 8.97  0.15 6.10  0.16 5.56  0.02 10.61  0.08 8.59  0.05
Gi1 1.86  0.17 1.44  0.06 1.16  0.01 4.82  0.08 4.92  0.35
Gi2 1.75  0.01 1.79  0.26 1.28  0.01 4.81  0.14 2.88  0.02
Gi3 3.39  0.16 2.69  0.06 2.26  0.06 7.02  0.09 8.06  0.14
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FIG. 5. G5/R7 proteins stimulate different maximal GTPase
activity. Steady state GTPase rates were determined for M2GoG12
vesicles in the presence of 100 M carbachol and various concentrations
of R7 proteins to generate concentration effect curves. Values observed
at each RGS concentration in the absence of vesicles have been sub-
tracted from the data. Data are plotted as GTPase rates (min1). Sym-
bols are G5/RGS11 (), G5/RGS9 (), G5/RGS7 (), and G5/RGS6
(f). Results are representative of at least three independent determi-
nations using three separate vesicle preparations.
FIG. 6. G5/R7 proteins exhibit differences in potency toward
Gi family G-subunits. Steady state GTPase rates were determined
for M2Gi/oG12 vesicles in the presence of 100 M carbachol and
various concentrations of R7 proteins to generate concentration effect
curves. Data are normalized to 100% activity for comparison of EC50
values. Symbols are G5/RGS11 (), G5/RGS9 (), G5/RGS7 (), and
G5/RGS6 (f). Results are representative of at least three independent
determinations using three separate vesicle preparations.
FIG. 4. G5/R7 proteins do not stimulate GTPase activity of Gq
family G-subunits. A, the effects of 100 M carbachol and 1 M of the
indicated RGS protein on the steady state GTPase activity of Gq and
G11 reconstituted in phospholipid vesicles with the M1 muscarinic
receptor and G12 were determined as described under “Experimental
Procedures.” Open bars, no agonist. Shaded bars, 100 M carbachol.
Results shown are representative of three separate experiments using
three independent vesicle preparations. B, the effects of 1 M G5/RGS
proteins on agonist-stimulated steady state GTPase activity of M1
receptor-coupled Gq and G11 were determined in the presence of 100
nM RGS4. The effects of heat inactivated G5/RGS11 were also deter-
mined. The results are presented as a percentage of the agonist-stim-
ulated activity.
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GAP activity and selectivities within this class of proteins remain
undefined.
Members of the G5/R7 family previously were reported to be
specific for Go in single turnover assays of soluble G-sub-
units (11, 20). These assays may not accurately represent phys-
iological interactions between G-proteins and RGS proteins for
several reasons including the lack of a lipid bilayer with which
G-proteins and RGS proteins may associate, the lack of a
GPCR, which may form a complex with RGS proteins (37–39)
and facilitate interaction with G-subunits, and the necessity
of using GTPase-deficient mutants of Gq family G-proteins
given their low rates of exchange. These limitations may ex-
plain discrepancies between selectivities for G-protein -sub-
units observed in single turnover versus cell-based assays. In-
deed, RGS2 behaves as a Gq-specific GAP in single turnover
assays, but exhibits GAP activity toward Gi as well as Gq in
steady state GTPase assays of proteoliposomes reconstituted
with GPCR and heterotrimeric G-proteins (28).
In this study, we examined the GAP activity of G5/R7 pro-
teins using steady state GTPase assays of receptor-coupled
G-proteins reconstituted in phospholipid bilayers. Because
these assays measure multiple rounds of hydrolysis in the
presence of receptor-stimulated guanine nucleotide exchange,
wild type Gq or G11 may be used, and the contributions made
by agonist, receptor, G-subunits, and the phospholipid bi-
layer to GTPase activity are likely more representative of a
cellular environment. Our results differ from those from single
turnover assays (11, 20) with respect to the selectivity within
the Gi/o family since all four G-subunits of this family are
substrates for G5/R7 proteins.
Our results also differ from published reports that indirectly
suggest that G5/R7 proteins stimulate GTPase activity of Gq
or G11 (14, 21, 22) in that we did not observe stimulation of
Gq or G11 GTPase activity in response to R7 proteins. A
trivial explanation for our observation is that R7 proteins in-
hibit agonist promoted exchange and thereby mask GAP activ-
ity in steady state GTPase assays. However, the lack of an
effect of R7 proteins on the steady state GTPase activity
achieved in the presence of carbachol and RGS4 demonstrates
that G5/R7 heterodimers do not significantly affect agonist-
promoted exchange of guanine nucleotides under the condi-
tions of these assays (Fig. 4B). We also observed minimal to no
effects of G5/R7 proteins on agonist-stimulated guanine nu-
cleotide exchange measured directly in GTPS binding assays
(not shown). Therefore, the inability of G5/R7 proteins to
stimulate steady state GTPase activity of Gq and G11 indi-
cates that they do not function as Gq family GAPs under the
conditions of our assay. In the absence of GAP activity, the
reported effects of RGS7 on Gq family G-protein signaling could
reflect direct inhibition of phospholipase enzymes, as observed
by Posner et al. (20). Although we have observed some inhibi-
tion of receptor-stimulated inositol phosphate accumulation in
cells cotransfected with R7 RGS proteins and G5, this inhibi-
tion is less pronounced and requires expression to much higher
levels than does the marked inhibition of phospholipase C
response observed in cells overexpressing RGS2 or RGS4 (data
not shown). Thus, the reported effects of R7 proteins on cellular
Gq pathways may reflect either loss of GAP selectivity due to
protein overexpression or a more complex interaction of G5/R7
dimers with the G-protein signaling cycle.
G5/R7 proteins exhibited differences in the potency and
efficacy of their GAP activity against the Gi/o family. G5/
RGS6 and G5/RGS7 each exhibited 10-fold lower potency for
Gi -subunits than for Go. In contrast, G5/RGS9 and G5/
RGS11 exhibited similar potency for all four Gi family G-
subunits. This pattern mirrors the grouping of R7 proteins by
sequence similarity; that is, RGS6 and RGS7 have higher se-
quence identity to each other than to RGS9 and RGS11 and vice
FIG. 7. G5/RGS7 and G5/RGS9 inhibit G5/RGS11-stimulated
GTPase activity of Go. A, steady state GTPase activity of
M2GoG12 vesicles was determined in the presence of 100 M car-
bachol alone or in the presence of G5/R7 proteins. The effects of 100 nM
G5/RGS11, 1 M G5/RGS7, and heat-inactivated G5/RGS7 (1 M)
were assayed separately and in combination. Results are representative
of two independent experiments with two RGS11 preparations. B, G5/
R11-stimulated steady state GTPase activity of Go was determined at
various concentrations of added G5/RGS7 and G5/RGS9.
TABLE II
EC50 values G5/R7 proteins for stimulation of GTPase activity
of Gi family G-subunits
The mean  S.D. of EC50 values (nM) are shown from three independ-
ent determinations of the concentration effect relationship of the R7
proteins as GAPs of Gi family G-subunits using three different vesicle
preparations.
G5/RGS6 G5/RGS7 G5/RGS9 G5/RGS11
Go 34  8.5 40  18 47  22 16  5.1
Gi1 160  84 240  110 56  23 38  5.0
Gi2 160  49 305  92 54  21 80  50
Gi3 180  57 351  45 27  11 43  7.0
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versa (13). The R7 proteins group differently with respect to
their apparent efficacies for stimulation of GTPase activity.
G5/RGS11 exhibited the highest maximal effect, while the
maximal effects of G5/RGS7 and G5/RGS9 were much less
and G5/RGS6 exhibited an intermediate maximal effect.
These differences in activity inversely correlate with the ex-
pression of R7 transcripts in rat brain where RGS11 is ex-
pressed at much lower levels than RGS7 and -9, and again
RGS6 is intermediate (42). We speculate that expression of the
robustly active RGS11 may be regulated differently than the
less active proteins.
Gi1, Gi2, and Gi3 share high sequence homology, and
these signaling proteins are essentially interchangeable in
many signaling processes. However, although these proteins
often are expressed in the same cell, they may not be entirely
functionally redundant. For example, selectivity of coupling of
certain G protein-coupled receptors among these three Gi
proteins has been illustrated (43–46), and several reports sug-
gest selective coupling of receptors to ion channels through
specific Gi-subunits (for review see Ref. 47). Our observation
of selectivity of action of 5/RGS proteins among Gi1, Gi2,
Gi3, and Gi/o likely has physiologically important ramifica-
tions. For example, this family of RGS proteins is highly ex-
pressed in the central nervous system as are Gi family G-
subunits. Given the broadly different patterns of expression of
RGS6, RGS7, RGS9, and RGS11 in the brain (42), we hypoth-
esize that otherwise functionally redundant Gi-subunits may
exhibit cell-specific differences in signaling activities as a con-
sequence of the presence of different RGS proteins.
The differences observed in the maximal GAP activity of R7
family RGS proteins may reflect differences in their interac-
tions with G. Unlike GAP proteins for the Ras superfamily
GTPases, which contribute a catalytic arginine required for
GTPase activity, RGS proteins are considered to enhance
GTPase activity solely by stabilizing G switch regions (48).
Presumably, R7 RGS proteins bind G-subunits through inter-
actions similar to those observed in the RGS4/Gi (48) and the
RGS9/Gt/i1 crystal structures (49), in which the base of a
4-helix bundle (4, 5, 6, 7) of the RGS domain directly
contacts portions of the three switch regions of G. Martemy-
anov and Arshavsky recently reported that mutation of RGS9
residues in the base of G-interacting helices 5 and 6 (L353E/
R360P) resulted in markedly higher maximal GAP activity
toward G transducin than observed in wild type RGS9, con-
sistent with a role for this region in determining maximal GAP
activity (50). It will be equally important to determine if re-
gions outside the RGS box play important roles in defining
selectivities of 5-RGS proteins among G-subunits as sug-
gested in studies of G selectivity of C. elegans R7 family
members (40, 41).
In summary, we have demonstrated that R7 family RGS
proteins selectively stimulate GTPase activity of Gi family G-
subunits. We have shown differences in potency and efficacy of
G5/R7 dimers as GAPs among the Gi family G-subunits.
Further, lower efficacy GAPs were shown to inhibit GTPase
activity achieved in the presence of a more efficacious GAP,
indicating that RGS proteins apparently interacting with the
same activating surface of a G-subunit promote different max-
imal rates of catalysis by the G GTPase.
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